Page 1513 - Williams Hematology ( PDFDrive )

1488 Part X: Malignant Myeloid Diseases Chapter 89: Chronic Myelogenous Leukemia and Related Disorders 1489

888. Giles FJ, Larson RA, Kantarjian HM, et al: Nilotinib in patients with Philadelphia 917. Apperley JF, Gardembas M, Melo JV, et al: Response to imatinib mesylate in patients
chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who with chronic myeloproliferative diseases with rearrangements of the platelet-derived
are resistant or intolerant to imatinib. J Clin Oncol 26:376, 2008. growth factor receptor beta. N Engl J Med 347:481, 2002.
889. Cortes J, Rousselot P, Kin DW, et al: Dasatinib induces complete hematologic and 918. Wessels JW, Fibbe WE, van der Keur D, et al: T(5;12)(q31;p12): A clinical entity with
cytogenetic responses in patients with imatinib-resistant or intolerant chronic features of both myeloid leukemia and chronic myelomonocytic leukemia. Cancer
myeloid leukemia in blast crisis. Blood 109:3207, 2007. Genet Cytogenet 65:7, 1993.
890. Nicolini FE, Khoury HJ, Akard L, et al: Omacetaxine mepesuccinate for patients with 919. Golub TR, Barker GF, Lovett HM, Gilliland DG: Fusion of PDGF receptor beta to a
accelerated phase chronic myeloid leukemia with resistance or intolerance to two or novel ets-like gen, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal
more tyrosine kinase inhibitors. Haematologica 29:e78, 2013. translocation. Cell 77:307, 1994.
891. Barone S, Baer MR, Sait SNJ, et al: High-dose cytosine arabinoside and idarubicin 920. Cross NCP, Reiter A: Tyrosine kinase genes in chronic myeloproliferative diseases.
treatment of chronic myeloid leukemia in myeloid blast crisis. Am J Hematol 67:119, Leukemia 16:1207, 2002.
2001. 921. Costa R, Abdulhaq H, Haq B, et al: Activity of azacitidine in chronic myelomonocytic
892. Thomas DA, O’Brien SM, Faderl S, et al: Long-term outcome after hyper-CVAD and leukemia. Cancer 117:2690, 2011.
imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive 922. Gunby RH, Cazzaniga G, Tassi E, et al: Sensitivity to imatinib but low frequency of the
acute lymphoblastic leukemia (Ph-ALL) J Clin Oncol 28: Abstract 6506, 2010. TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. Haematolog-
893. Benjamini O, Dumlao TL, Kantarjian H, O’Brien S, et al: Phase II trial of hyper CVAD ica 88:408, 2003.
and dasatinib in patients with relapsed Philadelphia chromosome positive acute lym- 923. Pitini V, Arrigo C, Teti D, et al: Response to STI571 in chronic myelomonocytic leuke-
phoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol 89:282, mia with platelet derived growth factor beta receptor involvement: A new case report.
2014. Haematologica 88:ECR18, 2003.
894. Champlain R, Ho W, Arenson E, Gale RP: Allogeneic bone marrow transplantation 924. Kröger N, Zabelina T, Guardiola P, et al: Allogeneic stem cell transplantation of adult
for chronic myelogenous leukemia in chronic or accelerated phase. Blood 60:1038, chronic myelomonocytic leukemia. Br J Haematol 118:67, 2002.
1982. 925. Onida F, Kantarjian HM, Smith TL, et al: Prognostic factors and scoring systems
895. McGlave PB, Kim TH, Hard DD, et al: Successful allogeneic bone-marrow transplan- in chronic myelomonocytic leukemia: A prospective analysis of 213 patients. Blood
tation for patients in the accelerated phase of chronic granulocytic leukaemia. Lancet 99:840, 2002.
2:625, 1982. 926. Germing U, Strupp C, Alvado M, Gattermann N: New prognostic parameters for
896. Martin PJ, Clift RA, Fisher LD, et al: HLA-identical marrow transplantation during chronic myelomonocytic leukemia? Blood 100:731, 2002.
accelerated-phase chronic myelogenous leukemia: Analysis of survival and remission 927. Sagaster V, Ohler L, Berer A, et al: High spontaneous colony growth in chronic myelo-
duration. Blood 77:1978, 1988. monocytic leukemia correlates with increased disease activity and is a novel prognos-
897. Falkenberg JHF, Wafelman AR, Joosten P, et al: Complete remission of accelerated tic factor for predicting short survival. Ann Hematol 83:9, 2004.
phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T 928. Stillman RG: A case of myeloid leukemia with predominance of eosinophil cells. Med
lymphocytes. Blood 94:1201, 1999. Rec 81:594, 1912.
898. Weisser M, Schleuning M, Haferlach C, et al: Allogeneic stem-cell transplantation 929. Benvenisti DS, Ultmann JE: Eosinophilic leukemia. Ann Intern Med 71:731, 1969.
provides excellent results in advanced stage chronic myeloid leukemia with major 930. Chusid MJ, Dale D, West BG, Wolff SM: The hypereosinophilic syndrome: Analysis of
cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma 48:295, fourteen cases with a review of the literature. Medicine (Baltimore) 54:1, 1975.
2007. 931. Brito-Babapulle F: The eosinophilias: Including the idiopathic hypereosinophilic syn-
899. Carella AM, Gaozza E, Raffo MR, et al: Therapy of acute phase chronic myelogenous drome. Br J Haematol 121:203, 2003.
leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporin A. 932. Robyn J, Lemery S, McCoy JP, et al: Multilineage involvement of the fusion gene in
Leukemia 5:517, 1991. patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol
900. Bouvet M, Babiera GV, Termuhlen PM, et al: Splenectomy in the accelerated or blas- 132:286, 2006.
tic phase of chronic myelogenous leukemia: A single-institution 25-year experience. 933. Crescenzi B, Chase A, Starza RL, et al: FIP1L1-PDGFRA in chronic eosinophilic leu-
Surgery 122:20, 1997. kemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
901. Wadhwa J, Szydio RM, Apperley J, et al: Factors affecting duration of survival after Leukemia 21:397, 2007.
onset of blastic transformation of chronic myeloid leukemia. Blood 99:2304, 2002. 934. Pardanani A, Brockman SR, Paternoster SF, et al: FIP1L1-PDGFRA fusion: Preva-
902. Majiis A, Smith TL, Talpaz M, et al: Significance of cytogenetic clonal evolution in lence and clinicopathologic correlates in 89 consecutive patients with moderate to
chronic myelogenous leukemia. J Clin Oncol 14:196, 1996. severe eosinophilia. Blood 104:3038, 2004.
903. Fialkow PJ, Jacobsen RJ, Singer JW, et al: Philadelphia chromosome (Ph1)-negative 935. Bain BJ: Cytogenetic and molecular genetic aspects of eosinophilic leukemia. Br J
chronic myelogenous leukemia (CML): A clonal disease with origin in a multipotent Haematol 122:173, 2003.
stem cell. Blood 56:70, 1980. 936. Gotlib J, Cools J, Malone JM III, et al: The FIP1L1-PDGFRA fusion tyrosine kinase
904. Such E, Germing U, Malcovati L, et al: Development and validation of a prognostic in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for
scoring system for patients with chronic myelomonocytic leukemia. Blood 121:3005, diagnosis, classification, and management. Blood 103:2879, 2004.
2013. 937. Vandenberghe P, Wlodarska I, Michaux L, et al: Clinical and molecular features of
905. Cortes J: CMML: A biologically distinct disease. Curr Hematol Rep 2:202, 2003. FIP1L1-PDFGRA (+) chronic eosinophilic leukemia. Leukemia 18:734, 2004.
906. Onida F, Beran M: Chronic myelomonocytic leukemia: Myeloproliferative variant. 938. Klion AD, Noel P, Akin C, et al: Elevated serum tryptase levels identify a subset of
Curr Hematol Rep 3:218, 2004. patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome
907. Gross SA, Irons RD, Scott PK, et al: A case-control study of chronic myelomonocytic associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood
leukemia (CMML) in Shanghai, China: Evaluation of risk factors for CMML, with 101:4660, 2003.
special focus on benzene. Arch Environ Occup Health 67:206, 2012. 939. Florian S, Esterbauer H, Binder T, et al: Systemic mastocytosis (SM) associated with
908. Takahashi K, Pemmaraju N, Strati P, et al: Clinical characteristics and outcomes of chronic eosinophilic leukemia (SM-CEL): Detection of FIP1L1/PDGFRalpha, classi-
therapy-related chronic myelomonocytic leukemia. Blood 122:2807, 2013. fication by WHO criteria, and response to therapy with imatinib. Leuk Res 30:1201,
909. Saif MW, Hopkins JL, Gore SD: Autoimmune phenomena in patients with myelodys- 2006.
plastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 43:2083, 940. Klion AD, Robyn J, Maric I, et al: Relapse following discontinuation of imatinib mesy-
2002. late therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: Implica-
910. Cambier N, Baruchel A, Schlageter MH, et al: Chronic myelomonocytic leukemia: tions for optimal dosing. Blood 110:3552, 2007.
From biology to therapy. Hematol Cell Ther 39:41, 1997. 941. Verstovsek S, Tefferi A, Cortes J, et al: Phase II study of dasatinib in Philadelphia
911. Stemmler J, Wittman GW, Hacker U, Heinemann V: Leukapheresis in chronic mye- chromosome-negative acute and chronic myeloid disease, including systemic masto-
lomonocytic leukemia with leukostasis syndrome: Elevated serum lactate levels as an cytosis. Clin Cancer Res 14:3906, 2008.
early sign of microcirculation failure. Leuk Lymphoma 43:1427, 2002. 942. Esteva-Lorenzo FJ, Meehan KR, Spitzer TR, Mazumder A: Allogeneic bone marrow
912. Bain BJ: Hypereosinophilia. Curr Opin Hematol 7:21, 2000. transplantation in a patient with hypereosinophilic syndrome. Am J Hematol 51:164,
913. Aguayo A, Kantarjian H, Manshouri T, et al: Angiogenesis in acute and chronic leuke- 1996.
mias and myelodysplastic syndromes. Blood 96:2240, 2000. 943. Juvonen E, Volin L, Koponen A, Ruutu T: Allogeneic blood stem cell transplanta-
914. Ramshaw HS, Bardy PG, Lee MA, Lopez AQF: Chronic myelomonocytic leukemia tion following non-myeloablative conditioning for hypereosinophilic syndrome. Bone
requires granulocytic-macrophage colony-stimulating factor for growth in vitro and Marrow Transplant 29:457, 2002.
in vivo. Exp Hematol 30:1124, 2002. 944. Plotz SG, Simon HU, Darsow U, et al: Use of anti-interleukin-5 antibody in the hyper-
915. Tessema M, Länger F, Dingemann J, et al: Aberrant methylation and impaired expres- eosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349:2334, 2003.
sion of the p14INK4B cell cycle regulatory gene in chronic myelomonocytic leukemia 945. Klion AD, Law MA, Noel P, et al: Safety and efficacy of the monoclonal anti-
(CMML). Leukemia 17:910, 2003. interleukin-5 antibody SCHJ55700 in the treatment of patients with hypereosino-
916. Magnusson MK, Meade KE, Nakamura R, et al: Activity of STI571 in chronic mye- philic syndrome. Blood 103:2939, 2004.
lomonocytic leukemia with a platelet-derived growth factor B receptor fusion onco- 946. Ardanani AD, Morice WG, Hoyer JD, Tefferi A: Chronic basophilic leukemia: A dis-
gene. Blood 100:1088, 2002. tinct clinical entity. Eur J Haematol 71:18, 2003.

Kaushansky_chapter 89_p1437-1490.indd 1488 9/18/15 3:42 PM